TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17418968

Group type: EXPERIMENTAL
Intervention: 20 mg of melatonin in the morning (8-9 AM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 20 mg of melatonin in the evening (8-9 PM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Historical control (whole-brain radiotherapy)
Number of subjects: 0
Study: 16599071

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) with adjuvant therapy (glycoprotein IIB/IIIA receptor inhibitors and clopidogrel)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fibrinolytic agents
Number of subjects: 0
Study: 11906689

Group type: EXPERIMENTAL
Intervention: Minimal-contact intervention (proactive phone contact, motivational interviewing, treatment manual, video, two supportive phone calls)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 60
Study: 10543294

Group type: EXPERIMENTAL
Intervention: Benzamil (1.7 x 10(‐3) M)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Amiloride (1 x 10(‐3) M)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (0.9% sodium chloride)
Number of subjects: 10
Study: 8749187

Group type: EXPERIMENTAL
Intervention: Sway-referenced visual tests (SOTs 3 + 6)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Eyes closed tests (SOTs 2 + 5)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Sway-referenced surfaces (SOTs 4, 5 & 6)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Sway-referenced support surfaces
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: All astronauts
Number of subjects: 23
Study: 1978373

Group type: EXPERIMENTAL
Intervention: Benztropine (BZ) at 2 mg i.m. and then 1 mg p.o. b.i.d. for 2 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 383107

Group type: EXPERIMENTAL
Intervention: Pervincamine + glycerol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Glycerol + placebo
Number of subjects: 20
Study: 30657186

Group type: EXPERIMENTAL
Intervention: Caffeine (80 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 28319243

Group type: EXPERIMENTAL
Intervention: Vitamin E
Number of subjects: 7540

Group type: EXPERIMENTAL
Intervention: Selenium
Number of subjects: 7540

Group type: EXPERIMENTAL
Intervention: Vitamin E and Selenium
Number of subjects: 7540

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7540
Study: 25922463

Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression (IPC) therapy for six hours per day (n = 74)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Treatment as usual in a plaster cast without IPC (n = 74)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression (IPC) therapy
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression (IPC) therapy (n = 74)
Number of subjects: 150
Study: 23528027

Group type: EXPERIMENTAL
Intervention: Glycoprotein IIb/IIIa inhibitors (GPIs) during TRA PCI
Number of subjects: 910
Study: 21663617

Group type: EXPERIMENTAL
Intervention: Wet-cupping treatment
Number of subjects: 32

Group type: COMPARATOR
Intervention: Waiting-list group
Number of subjects: 32
Study: 20180330

Group type: EXPERIMENTAL
Intervention: LASIK
Number of subjects: 27

Group type: COMPARATOR
Intervention: PRK
Number of subjects: 27
Study: 18220025

Group type: EXPERIMENTAL
Intervention: Ariphon retard (Servier)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Prestarium
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 81
Study: 15671702

Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 4029

Group type: COMPARATOR
Intervention: Nonusers of Hormone Replacement Therapy (HRT)
Number of subjects: 4029
Study: 11549228

Group type: EXPERIMENTAL
Intervention: Smoking (ad lib)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Smoking abstinence
Number of subjects: 26

Group type: COMPARATOR
Intervention: Non-smokers
Number of subjects: 26
Study: 9199952

Group type: EXPERIMENTAL
Intervention: Enoximone echocardiography (1 mg/kg over 5 min)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Dobutamine echocardiography (up to 15 micrograms/kg/min)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Enoximone echocardiography
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Follow-up echocardiogram
Number of subjects: 10
Study: 8179735

Group type: EXPERIMENTAL
Intervention: Metoclopramide (10 mg syrup)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo (equivalent volume)
Number of subjects: 11
Study: 3648692

Group type: EXPERIMENTAL
Intervention: Controlled supplemental oxygenation (Procedure B)
Number of subjects: 16

Group type: COMPARATOR
Intervention: No supplemental oxygenation (Procedure A)
Number of subjects: 16
Study: 31701481

Group type: EXPERIMENTAL
Intervention: Elotuzumab plus lenalidomide and dexamethasone (ELd)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Lenalidomide and dexamethasone (Ld)
Number of subjects: 82
Study: 30082359

Group type: EXPERIMENTAL
Intervention: CADL (client-centred activities of daily living)
Number of subjects: 110

Group type: COMPARATOR
Intervention: UADL (usual activities of daily living)
Number of subjects: 110
Study: 28254958

Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 61

Group type: COMPARATOR
Intervention: Quetiapine
Number of subjects: 61
Study: 26256964

Group type: EXPERIMENTAL
Intervention: Triflusal (300 mg, b.i.d.)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Aspirin (150 mg, b.i.d.)
Number of subjects: 88
Study: 24228528

Group type: EXPERIMENTAL
Intervention: Immune 2 plus HAART
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (HIV negative healthy donors)
Number of subjects: 37
Study: 21413846

Group type: EXPERIMENTAL
Intervention: COPE problem solving model educational intervention; three conjoint educational sessions during the first month.
Number of subjects: 476

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 476
Study: 18349393

Group type: EXPERIMENTAL
Intervention: FLO (fluorouracil 2,600 mg/m(2) via 24‐hour infusion, leucovorin 200 mg/m(2), oxaliplatin 85 mg/m(2) every 2 weeks)
Number of subjects: 220

Group type: COMPARATOR
Intervention: FLP (fluorouracil 2,000 mg/m(2) via 24‐hour infusion, leucovorin 200 mg/m(2) weekly, cisplatin 50 mg/m(2) every 2 weeks)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: FLO in patients older than 65 years
Number of subjects: 220
Study: 16478005

Group type: EXPERIMENTAL
Intervention: Glomox tablet (test)
Number of subjects: 24

Group type: COMPARATOR
Intervention: amoxicillin capsule (reference)
Number of subjects: 24
Study: 15033211

Group type: EXPERIMENTAL
Intervention: Telephone (one meeting with a therapist plus three telephone contacts)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Group cognitive-behavior therapy (Group)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Telephone
Number of subjects: 28

Group type: COMPARATOR
Intervention: Group
Number of subjects: 28
Study: 11158283

Group type: EXPERIMENTAL
Intervention: Angiotensin II (1, 3, 6 and 10 ng kg‐1 min‐1)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Noradrenaline (10, 30, 60 and 100 ng kg‐1 min‐1)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 9497755

Group type: EXPERIMENTAL
Intervention: Computer-based RPD design simulations
Number of subjects: 36

Group type: COMPARATOR
Intervention: Faculty-led small-group seminars
Number of subjects: 36
Study: 8421475

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (1000 mg per day)
Number of subjects: 122
Study: 3321483

Group type: EXPERIMENTAL
Intervention: Ketamine 0.5 mg/kg intravenously before operation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 40
Study: 31702047

Group type: EXPERIMENTAL
Intervention: 15 g glucose
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 20 g glucose
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 25 g glucose
Number of subjects: 6
Study: 30377184

Group type: EXPERIMENTAL
Intervention: Dexcom G5 Mobile continuous glucose monitoring (CGM) system with remote monitoring
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional blood glucose monitoring (control)
Number of subjects: 0
Study: 26902618

Group type: EXPERIMENTAL
Intervention: Pre-clipping injection group (PG)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Conventional injection group (CG)
Number of subjects: 81
Study: 24451883

Group type: EXPERIMENTAL
Intervention: Immediately loaded implants
Number of subjects: 155

Group type: COMPARATOR
Intervention: Delayed loaded implants
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Flapless surgical technique
Number of subjects: 155

Group type: COMPARATOR
Intervention: Full-thickness flap technique
Number of subjects: 155
Study: 22176029

Group type: EXPERIMENTAL
Intervention: Immediate RNA isolation after tooth extraction
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Liquid nitrogen (24 h)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: -80 °C (24 h)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 20 °C (24 h)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 4 °C (6 h)
Number of subjects: 15
Study: 21246922

Group type: EXPERIMENTAL
Intervention: Dexamethasone, 0.15 mg/kg every 6 hours for 4 days
Number of subjects: 147

Group type: COMPARATOR
Intervention: Control group (not treated with dexamethasone)
Number of subjects: 147
Study: 19026268

Group type: EXPERIMENTAL
Intervention: Citalopram (SSRI)
Number of subjects: 2875
Study: 16189969

Group type: EXPERIMENTAL
Intervention: SVD-based optimal filtering technique
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adaptive beamformer
Number of subjects: 0
Study: 12594304

Group type: EXPERIMENTAL
Intervention: CVD 908-htrA high dose (4.5 x 10(8) CFU)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: CVD 908-htrA low dose (5 x 10(7) CFU)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: CVD 908-htrA (both doses)
Number of subjects: 8
Study: 11783226

Group type: EXPERIMENTAL
Intervention: Composite Xiansu Capsule (CXSC) combined with chemotherapy
Number of subjects: 61

Group type: COMPARATOR
Intervention: Chemotherapy alone (Control)
Number of subjects: 61
Study: 7502997

Group type: EXPERIMENTAL
Intervention: Workers cognizant of the study
Number of subjects: 1088

Group type: EXPERIMENTAL
Intervention: 7-day recall period
Number of subjects: 1088

Group type: EXPERIMENTAL
Intervention: Females
Number of subjects: 1088

Group type: COMPARATOR
Intervention: Overall SBS prevalence
Number of subjects: 1088
Study: 2681676

Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine gluconate mouthrinse (Peridex)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 30785844

Group type: EXPERIMENTAL
Intervention: FlexDex (FD)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Standard Laparoscopy (SL)
Number of subjects: 22
Study: 27876583

Group type: EXPERIMENTAL
Intervention: Operative stabilization by pediatric orthopedists (Group A)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Operative stabilization by non-pediatric orthopedists (Group B)
Number of subjects: 88
Study: 25498417

Group type: EXPERIMENTAL
Intervention: Methylphenidate (40 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: MDMA (75 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 24094274

Group type: EXPERIMENTAL
Intervention: Psychological treatments (specific types not detailed)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study: 21897859

Group type: EXPERIMENTAL
Intervention: Subway air exposure in healthy individuals
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Subway air exposure in asthmatics
Number of subjects: 64

Group type: COMPARATOR
Intervention: Ambient air exposure
Number of subjects: 64
Study: 19682661

Group type: EXPERIMENTAL
Intervention: Rivastigmine 3-12 mg/d capsules
Number of subjects: 1018

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1018
Study: 17430256

Group type: EXPERIMENTAL
Intervention: 0.1% captopril gel
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: 0.5% captopril gel
Number of subjects: 56

Group type: COMPARATOR
Intervention: placebo gel
Number of subjects: 56
Study: 11160953

Group type: EXPERIMENTAL
Intervention: Lamotrigine 200 mg/d
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lamotrigine 25 mg/d
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lamotrigine 50 mg/d
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lamotrigine 100 mg/d
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 9951857

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy (5-fluorouracil 200 mg/m2, doxorubicin 15 mg/m2, mitomycin 5 mg/m2)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group (palliative surgery only)
Number of subjects: 83
Study: 8310507

Group type: EXPERIMENTAL
Intervention: 33B3.1 monoclonal antibody (10 mg/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Rabbit antithymocyte globulin (ATG) (1.5 mg/kg/day)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 33B3.1 monoclonal antibody
Number of subjects: 40

Group type: COMPARATOR
Intervention: Rabbit antithymocyte globulin (ATG)
Number of subjects: 40
Study: 3747335

Group type: EXPERIMENTAL
Intervention: Corticosteroids (prednisolone) at an initial dose of 60 mg/24 hr for 8 weeks
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Number of subjects: 89
Study: 29747597

Group type: EXPERIMENTAL
Intervention: Physical activity group (14 sessions of treadmill exercise and physical activity consultations)
Number of subjects: 784

Group type: COMPARATOR
Intervention: Usual care (six-weekly sessions of smoking cessation behavioural-support)
Number of subjects: 784
Study: 27449894

Group type: EXPERIMENTAL
Intervention: Individual Placement and Support (IPS)
Number of subjects: 0
Study: 24457911

Group type: EXPERIMENTAL
Intervention: EC-DT (epirubicin plus cyclophosphamide followed by docetaxel plus trastuzumab)
Number of subjects: 102

Group type: COMPARATOR
Intervention: EC-DL (epirubicin plus cyclophosphamide followed by docetaxel plus lapatinib)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: EC-DT
Number of subjects: 102

Group type: COMPARATOR
Intervention: EC-DL
Number of subjects: 102
Study: 23307525

Group type: EXPERIMENTAL
Intervention: Physician-pharmacist collaborative intervention
Number of subjects: 496

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 496
Study: 19922458

Group type: EXPERIMENTAL
Intervention: Cilostazol 100 mg twice daily
Number of subjects: 244

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 244
Study: 19032914

Group type: EXPERIMENTAL
Intervention: Early use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers
Number of subjects: 0
Study: 18249214

Group type: EXPERIMENTAL
Intervention: New American Diabetes Association definition for impaired fasting glucose (IFG)
Number of subjects: 1034

Group type: COMPARATOR
Intervention: Initial fasting plasma glucose (FPG) values <100 mg/dL
Number of subjects: 1034

Group type: COMPARATOR
Intervention: Initial fasting plasma glucose (FPG) values 100 to 109 mg/dL
Number of subjects: 1034

Group type: COMPARATOR
Intervention: Initial fasting plasma glucose (FPG) values 110 to 125 mg/dL
Number of subjects: 1034

Group type: EXPERIMENTAL
Intervention: New definition of IFG including persons with FPG 100 to 109 mg/dL
Number of subjects: 1034

Group type: EXPERIMENTAL
Intervention: Fasting plasma glucose levels from 64 to 125 mg/dL
Number of subjects: 1034
Study: 15204121

Group type: EXPERIMENTAL
Intervention: Item recognition test (Experiments 1, 3a, and 4)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Relative recency decision task (Experiments 2, 3b, and 5)
Number of subjects: 0
Study: 11420590

Group type: EXPERIMENTAL
Intervention: Intramuscular betamethasone 12 mg
Number of subjects: 171

Group type: COMPARATOR
Intervention: Oral prednisone 50 mg daily for seven days
Number of subjects: 171
Study: 9349933

Group type: EXPERIMENTAL
Intervention: Intravenous 6-mercaptopurine (1 g.m-2: bolus dose of 0.2 g.m-2 followed by an 8-h infusion of 0.8 g.m-2)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Oral 6-mercaptopurine (50-165 mg.m-2.day-1)
Number of subjects: 11
Study: 8349376

Group type: EXPERIMENTAL
Intervention: Nicardipine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Combination of Nicardipine and Atenolol
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 2427862

Group type: EXPERIMENTAL
Intervention: Celiprolol 200 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Atenolol 100 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Metoprolol 200 mg
Number of subjects: 18
Study: 31112104

Group type: EXPERIMENTAL
Intervention: Ramping protocol (first 1,000 shocks at energy level 5, followed by 1,000 shocks at energy level 6, and 1,000 final shocks at energy level 7)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Fixed voltage protocol (all 3,000 shocks at energy level 7)
Number of subjects: 300
Study: 28706168

Group type: EXPERIMENTAL
Intervention: Violence Coping Program (VCP)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 36
Study: 26445137

Group type: EXPERIMENTAL
Intervention: Treadmill based visual cue training (T-VCT)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Over-ground visual cue training (O-VCT)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 56
Study: 23649799

Group type: EXPERIMENTAL
Intervention: 8-week exercise programme
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 46
Study: 21854552

Group type: EXPERIMENTAL
Intervention: Coblation tonsillectomy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Electrocautery tonsillectomy
Number of subjects: 80
Study: 20183391

Group type: EXPERIMENTAL
Intervention: Clinician-assisted emotional disclosure therapy
Number of subjects: 0
Study: 16204287

Group type: EXPERIMENTAL
Intervention: Agalsidase alfa (0.2 mg/kg) infused intravenously every other week for 4-4.5 years
Number of subjects: 25
Study: 15326238

Group type: COMPARATOR
Intervention: Normal Glucose (NG)
Number of subjects: 7027

Group type: EXPERIMENTAL
Intervention: Impaired Fasting Glucose (IFG)
Number of subjects: 7027

Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 7027
Study: 12555510

Group type: EXPERIMENTAL
Intervention: Naftidrofuryl 200 mg tid
Number of subjects: 182

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182
Study: 9404334

Group type: EXPERIMENTAL
Intervention: Variety Index for Toddlers (VIT)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Bread group
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Vegetable group
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Meat group
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: VIT scores
Number of subjects: 124
Study: 8099978

Group type: EXPERIMENTAL
Intervention: Timing principle group (vecuronium 0.15 mg.kg‐1 followed by thiopental 5 mg.kg‐1, intubation 60 seconds after thiopental)
Number of subjects: 40

Group type: COMPARATOR
Intervention: SCC group (thiopental 5 mg.kg‐1 followed by SCC 1 mg.kg‐1 after loss of consciousness)
Number of subjects: 40
Study: 3654234

Group type: EXPERIMENTAL
Intervention: Health education program for children with asthma
Number of subjects: 239

Group type: COMPARATOR
Intervention: Control group (no health education program)
Number of subjects: 239
Study: 29767793

Group type: EXPERIMENTAL
Intervention: Combined house dust and ozone exposure
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Ozone alone
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: House dust alone
Number of subjects: 23
Study: 27978834

Group type: EXPERIMENTAL
Intervention: Real acupuncture at abdominal point ST 25
Number of subjects: 321

Group type: COMPARATOR
Intervention: Park Sham at abdominal point ST 25
Number of subjects: 321

Group type: COMPARATOR
Intervention: Needle + foam at abdominal point ST 25
Number of subjects: 321

Group type: COMPARATOR
Intervention: Insertion and removal at abdominal point ST 25
Number of subjects: 321

Group type: COMPARATOR
Intervention: Real + Park Sham at abdominal point ST 25
Number of subjects: 321

Group type: COMPARATOR
Intervention: Real + needle and foam at abdominal point ST 25
Number of subjects: 321

Group type: COMPARATOR
Intervention: Real + insertion and removal at abdominal point ST 25
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Real acupuncture at lumbar point Bl 52
Number of subjects: 321

Group type: COMPARATOR
Intervention: Park Sham at lumbar point Bl 52
Number of subjects: 321

Group type: COMPARATOR
Intervention: Needle + foam at lumbar point Bl 52
Number of subjects: 321

Group type: COMPARATOR
Intervention: Insertion and removal at lumbar point Bl 52
Number of subjects: 321

Group type: COMPARATOR
Intervention: Real + Park Sham at lumbar point Bl 52
Number of subjects: 321

Group type: COMPARATOR
Intervention: Real + needle and foam at lumbar point Bl 52
Number of subjects: 321

Group type: COMPARATOR
Intervention: Real + insertion and removal at lumbar point Bl 52
Number of subjects: 321
Study: 24113152

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Sham TENS
Number of subjects: 82

Group type: COMPARATOR
Intervention: Untreated control
Number of subjects: 82
Study: 22591724

Group type: EXPERIMENTAL
Intervention: Inhalation of hyperpolarized (129)Xe gas mixed with (4)He gas (500 mL each)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Inhalation of hyperpolarized (129)Xe gas
Number of subjects: 33
Study: 20729301

Group type: EXPERIMENTAL
Intervention: Day 1 measurement of total cholesterol
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Day 1 measurement of triglycerides
Number of subjects: 128

Group type: COMPARATOR
Intervention: Combined data from literature review
Number of subjects: 128
Study: 18671864

Group type: EXPERIMENTAL
Intervention: Bright blue light therapy (BLT)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Dim red light (placebo)
Number of subjects: 126
Study: 15941372

Group type: EXPERIMENTAL
Intervention: Standard trauma craniectomy (STC)
Number of subjects: 486

Group type: COMPARATOR
Intervention: Limited craniectomy (LC)
Number of subjects: 486
Study: 12150498

Group type: EXPERIMENTAL
Intervention: Sildenafil (50 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sildenafil (suspected)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (suspected)
Number of subjects: 12